Temozolomide

Results: 176



#Item
1Lettre d’information du réseau GCO - Spéciale ASCOLes Groupes Coopérateurs en Oncologie à l’ASCO 2016 Les Groupes Coopérateurs en Oncologie (GCO) seront représentés au 52ème congrès de l’ASCO (Ameri

Lettre d’information du réseau GCO - Spéciale ASCOLes Groupes Coopérateurs en Oncologie à l’ASCO 2016 Les Groupes Coopérateurs en Oncologie (GCO) seront représentés au 52ème congrès de l’ASCO (Ameri

Add to Reading List

Source URL: www.gco-cancer.org

Language: English - Date: 2016-05-31 04:09:26
2Leading Edge  Perspective Improving Cancer Treatment via Mathematical Modeling: Surmounting the Challenges Is Worth the Effort

Leading Edge Perspective Improving Cancer Treatment via Mathematical Modeling: Surmounting the Challenges Is Worth the Effort

Add to Reading List

Source URL: michorlab.dfci.harvard.edu

Language: English - Date: 2015-11-19 11:48:55
3Adv Ther):DOIs12325ORIGINAL RESEARCH  AVAglio: Phase 3 Trial of Bevacizumab Plus Temozolomide

Adv Ther):DOIs12325ORIGINAL RESEARCH AVAglio: Phase 3 Trial of Bevacizumab Plus Temozolomide

Add to Reading List

Source URL: neurooncology.ucla.edu

Language: English - Date: 2011-08-25 16:23:45
    4Please stand by for realtime transcripts. >> [Captioner on Stand By]. >> Dr. Paleologos will answer as many questions as possible at the end of the presentation. Tomorrow, you will receive an invitation to complete a bri

    Please stand by for realtime transcripts. >> [Captioner on Stand By]. >> Dr. Paleologos will answer as many questions as possible at the end of the presentation. Tomorrow, you will receive an invitation to complete a bri

    Add to Reading List

    Source URL: www.abta.org

    Language: English - Date: 2014-04-11 12:09:34
    5A Phase 1 Study of Niraparib in Combination with Temozolomide (TMZ) in Patients with Advanced Cancer Poster 2092 R. Kurzrock , E. Galanis , M. Menfee , D. Johnson , K. Wilcoxin , T. McClure , V. Kansra , S. Agarwal , R.

    A Phase 1 Study of Niraparib in Combination with Temozolomide (TMZ) in Patients with Advanced Cancer Poster 2092 R. Kurzrock , E. Galanis , M. Menfee , D. Johnson , K. Wilcoxin , T. McClure , V. Kansra , S. Agarwal , R.

    Add to Reading List

    Source URL: www.tesarobio.com

    Language: English - Date: 2014-05-28 15:37:39
      6ABT-888 enhances cytotoxic effects of temozolomide independent of MGMT status in serum free cultured glioma cells

      ABT-888 enhances cytotoxic effects of temozolomide independent of MGMT status in serum free cultured glioma cells

      Add to Reading List

      Source URL: www.translational-medicine.com

      Language: English
        7Radiochemoimmunotherapy with intensity-modulated concomitant boost: interim analysis of the REACH trial

        Radiochemoimmunotherapy with intensity-modulated concomitant boost: interim analysis of the REACH trial

        Add to Reading List

        Source URL: www.ro-journal.com

        Language: English
        8REPRINT FROM APRIL 27, 2015  CLINICAL NEWS CLINICAL STATUS Provectus Biopharmaceuticals Inc. (NYSE-M:PVCT), Knoxville, Tenn.

        REPRINT FROM APRIL 27, 2015 CLINICAL NEWS CLINICAL STATUS Provectus Biopharmaceuticals Inc. (NYSE-M:PVCT), Knoxville, Tenn.

        Add to Reading List

        Source URL: www.pvct.com

        Language: English - Date: 2015-05-04 14:21:06
        9Public Policy Issue Brief Appropriations for Medical Research and Drug Approval: Ensuring Support for Brain Tumor Research and Drug Development Background •	 There have been very few new brain tumor therapies approved

        Public Policy Issue Brief Appropriations for Medical Research and Drug Approval: Ensuring Support for Brain Tumor Research and Drug Development Background • There have been very few new brain tumor therapies approved

        Add to Reading List

        Source URL: braintumor.org

        Language: English - Date: 2015-06-03 19:17:29
        10REPRINT FROM APRIL 27, 2015  CLINICAL NEWS CLINICAL STATUS Provectus Biopharmaceuticals Inc. (NYSE-M:PVCT), Knoxville, Tenn.

        REPRINT FROM APRIL 27, 2015 CLINICAL NEWS CLINICAL STATUS Provectus Biopharmaceuticals Inc. (NYSE-M:PVCT), Knoxville, Tenn.

        Add to Reading List

        Source URL: www.pvct.com

        Language: English - Date: 2015-05-04 14:21:06